ANALYSIS - The first signs are emerging of an impeding trade war between the EU and the US over the use of the growth promoter, ractopamine, which is used in turkeys and other livestock. With low stocks, a poor maize harvest this year look likely to lead to shortages until the next harvest. An outbreak of highly pathogenic bird flu has hit a farm in southern India and a village poultry flock in Bhutan.
The EU and US could be heading for another trade war, similar to the one it had over the use of growth hormones in beef cattle but this time, the row is brewing over the use of ractopamine - a beta-agonist - as a feed supplement, which is used for boosting growth and increasing leanness in pigs, cattle and turkeys.
The latest turn of events in this saga came last week, when the Council of the European Union published its official response to the decision by Codex Alimentarius to set maximum residue limits for ractopamine, thus endorsing its use.
The decision by Codex was taken after a majority vote by the member nations. The majority was two.
The anger from the European Union at the Codex decision and the response by the council puts the EU on a collision course with countries such as the US and Canada, where the use of ractopamine is widespread. Some estimates have the use in pig feed of between 60 and 80 per cent of the US herd.
The European Union has stuck to its policy of refusing access to meat from animals that have been treated with ractopamine and has called for assurances that any meat entering the EU from countries where its use is common has come from animals that are free from the drug.
The EU stance is also supported by China, where the import of products for animals treated with ractopamine is also banned.
There is also a divergence between the maximum residue levels that have been set down by Codex Alimentarius and the US.
The more the two sides dig in, the greater the divergence and hostility will emerge - and all this occurred at a time when the US meat companies were in Paris at one of the largest European food shows, marketing their products that had just been allowed onto the EU market in greater amounts following the compromise in the beef hormone dispute.
The latest turn of events in this saga came last week, when the Council of the European Union published its official response to the decision by Codex Alimentarius to set maximum residue limits for ractopamine, thus endorsing its use.
The decision by Codex was taken after a majority vote by the member nations. The majority was two.
The anger from the European Union at the Codex decision and the response by the council puts the EU on a collision course with countries such as the US and Canada, where the use of ractopamine is widespread. Some estimates have the use in pig feed of between 60 and 80 per cent of the US herd.
The European Union has stuck to its policy of refusing access to meat from animals that have been treated with ractopamine and has called for assurances that any meat entering the EU from countries where its use is common has come from animals that are free from the drug.
The EU stance is also supported by China, where the import of products for animals treated with ractopamine is also banned.
There is also a divergence between the maximum residue levels that have been set down by Codex Alimentarius and the US.
The more the two sides dig in, the greater the divergence and hostility will emerge - and all this occurred at a time when the US meat companies were in Paris at one of the largest European food shows, marketing their products that had just been allowed onto the EU market in greater amounts following the compromise in the beef hormone dispute.
